Insights on R/R Multiple Myeloma Treatment Decisions - priME Oncology
Webcast
Webcast

Insights on R/R Multiple Myeloma Treatment Decisions

Fitting the Pieces Together

Not a member of My prIME? Join now for instant access.

Watch our symposium webcast to enhance your understanding of the treatment of patients with relapsed/refractory multiple myeloma (R/R MM) with a focus on immunotherapy along with treatment selection and sequencing in the R/R disease setting.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.0 AMA PRA Category 1 Credit™

Release Date

Release Date

May 24, 2018

Expiration Date

May 24, 2019

Hot topic in MM: The evolving role for immunotherapy in patients with R/R disease
Pieter Sonneveld, MD, PhD on behalf of Gareth Morgan, MD, PhD, FRCP, FRCPath

Weighing the options at first relapse
Hermann Einsele, MD

How do I choose? Treatment decisions after multiple lines of therapy
Meletios Dimopoulos, MD

prIME Points™
Pieter Sonneveld, MD, PhD

  • Meletios Dimopoulos, MDUniversity of Athens
    Athens, Greece
  • Hermann Einsele, MDJulius Maximilian University of Würzburg
    Würzburg, Germany
  • Gareth Morgan, MD, PhD, FRCP, FRCPathUniversity of Arkansas for Medical Sciences
    Little Rock, Arkansas, United States
  • Pieter Sonneveld, MD, PhDErasmus Medical Center Cancer Institute
    Rotterdam, the Netherlands

This activity is intended for hematologists, oncologists, and other healthcare professionals involved in the management of patients with MM.

After successful completion of this educational activity, participants should be able to:

  • Discuss the rationale and mechanism of action for emerging immunotherapy options in the treatment of R/R MM
  • Evaluate recent clinical trial data investigating the efficacy and safety of novel doublet and triplet regimens and employ best practices in the selection of these regimens in the treatment of R/R MM
  • Describe the factors that influence treatment selection and sequencing in the R/R disease setting
  • Identify important ongoing clinical trials investigating novel treatment approaches for R/R MM

This educational activity is supported by a grant from Bristol-Myers Squibb.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Insights on R/R Multiple Myeloma Treatment Decisions - prIME Oncology

prIME Oncology designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This educational activity is supported by a grant from Bristol-Myers Squibb.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Dimopoulos has disclosed he has received honoraria or consultation fees from Amgen, Celgene, Janssen, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Einsele has disclosed that he has received fees for grants/research support, honoraria or consultation fees, and advisory board participation from Amgen, Bristol-Myers Squibb, Celgene, and Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Morgan has no relevant financial relationship to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Sonneveld has disclosed that he has received grants/research support from Amgen, Celgene, Janssen, Karyopharm, Skyline Dx, and Takeda. He also disclosed that he has received honoraria or consultation fees from Amgen, Celgene, Janssen, Karyopharm, and Takeda. Dr Sonneveld participated in advisory boards for Amgen, Celgene, Janssen, Karyopharm, Skyline Dx, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.